Manufacturer
19 recalls in our database name Major Pharmaceuticals as the manufacturing or recalling firm.
Of the 19 recalls from Major Pharmaceuticals we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 11 (58%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Major Pharmaceuticals is voluntarily recalling Levothyroxine Sodium Tablets, 75 mcg, NDC 0904-6951-61, due to subpotency. The recall affects lots N02172, N02296, and N02288 with expiration dates in July and December 2026, distributed nationwide.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 50 mcg, due to subpotency. The recall affects nationwide distribution in the USA and involves specific lot numbers.
Major Pharmaceuticals is voluntarily recalling Levothyroxine Sodium 125 mcg tablets (Lot N02266, Exp. 11/2026) nationwide due to subpotency, meaning the tablets may contain less active ingredient than labeled.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 25 mcg, lot N02212, due to subpotency. The recall is nationwide and voluntary.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 150 mcg, lot N02167, due to subpotent drug concerns. The recall affects nationwide distribution in the USA.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 25 mcg, due to subpotency. The recall affects nationwide U.S. distribution of specific lot numbers.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 112 mcg, lot N02203, due to subpotent drug concerns. The recall affects nationwide U.S. distribution and was initiated voluntarily by the firm.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 88 mcg, lot N02310, due to subpotency. The recall is voluntary and affects nationwide distribution in the USA.
Major Pharmaceuticals is voluntarily recalling certain lots of Levothyroxine Sodium Tablets (75 mcg) because the medication may be subpotent.
Major Pharmaceuticals is voluntarily recalling Levothyroxine Sodium Tablets (50 mcg) from lot N02200 due to subpotency, meaning the tablets may contain less active ingredient than labeled. Products were distributed nationwide in the USA.
Major Pharmaceuticals is voluntarily recalling Levothyroxine Sodium Tablets (125 mcg) because the medication may be subpotent.
Major Pharmaceuticals is recalling LEVOTHYROXINE SODIUM 150 mcg tablets because some batches contain less active ingredient than labeled, potentially reducing thyroid hormone effectiveness.
Major Pharmaceuticals is recalling 828 cartons of Divalproex Sodium Extended-Release Tablets because they were exposed to high humidity during packaging.
Major Pharmaceuticals is recalling Losartan Potassium 50 mg tablets because FDA testing found an impurity above acceptable levels.
Major Pharmaceuticals is recalling Doxycycline Hyclate 100 mg tablets because they failed to meet dissolution specifications.
Major Pharmaceuticals is recalling specific lots of 160 mg Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Major Pharmaceuticals is recalling specific lots of 80 mg Valsartan tablets because a carcinogen impurity was detected in the active ingredient.
Major Pharmaceuticals is recalling specific lots of Enalapril Maleate Tablets, 2.5 mg, because the product failed impurity specifications for a degradation product.
Major Pharmaceuticals is recalling 5,933 cartons of Enalapril Maleate Tablets, 5 mg, due to out-of-specification degradation products.